Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venanprubart (LY3361237) Phase 1 in SLE
NCT03933943Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing LY3361237 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug. Started May 2019; status: completed.
02
Drugs
venanprubart
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03933943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933943.